07.11.16
Headquarters: Indianapolis, IN
twitter.com/EliLillyCo
www.lilly.com
Headcount: 41,000
Year Established: 1876
Revenues: $19,959 (+2%)
Net Income: $2,408 (+1%)
R&D: $4,796 (+1%)
TOP SELLING DRUGS
In 2015 Lilly returned to revenue growth, led by Cyramza and Trulicity following their launches, with significant contributions from its enlarged animal health business, which got a boost after it completed the acquisition of Novartis Animal Health for $5.28 billion at the start of the year under review. Revenue increased 2 percent to $19.96 billion, with six products topping $1 billion in annual sales.
Lilly also reported positive advances in its pipeline of molecules in clinical development. Highlights include: in diabetes, positive cardiovascular outcomes data for Jardiance; in immunology, four positive Phase III studies on baricitinib and strong Phase III data on ixekizumab; and in oncology, Breakthrough Therapy Designation for olaratumab and abemaciclib, several important business development deals in immuno-oncology, and the approval of Portrazza for the treatment of metastatic squamous non-small cell lung cancer late in the year.
The year was active for Lilly on the collaboration front, which saw it expand already existing agreements and form new alliances as well. With Innovent Biologics, Lilly has in place a plan to develop and commercialize a portfolio of cancer treatments. In 2015 the two companies expanded the drug development collaboration, already one of the largest in China between a multi-national and domestic biopharmaceutical company. The companies said they will collaborate to support the development and potential commercialization of up to three anti-PD-1 based bispecific antibodies for cancer treatments over the next decade, both inside and outside of China. Lilly will exercise its rights to develop, manufacture and commercialize these potential cancer treatments outside of China, while Innovent will now have the rights to develop, manufacture and commercialize these potential cancer treatments for China.
Also in China, WuXi PharmaTech (Cayman) and Lilly entered into a strategic collaboration to develop, manufacture and commercialize a novel small molecule. The once-daily oral agent, discovered by Lilly, has the potential to address cardiovascular risk in patients with dyslipidemia. An estimated 276 million patients in China are affected by these conditions. The drug aims to reduce cardiovascular events in patients with elevated LDL cholesterol and triglycerides at high risk of cardiovascular events. WuXi will be responsible for regulatory, development and manufacturing activities in China and Lilly will be responsible for commercial activities. Both companies will invest in this potential new medicine in China. An Investigational New Drug (IND) application will be filed in China by WuXi, and product development and registration will take place within China.
A collaboration agreement was formed with Hanmi to develop and commercialize Hanmi’s compound being investigated for the treatment of autoimmune and other diseases. Lilly received rights to the molecule for all indications on a worldwide basis excluding China, Hong Kong, Taiwan, and Korea, and will be responsible for leading development, regulatory, manufacturing, and commercial efforts in our territories.
Another research collaboration with BioNTech aims to discover novel cancer immunotherapies. The companies will collaborate to identify and validate tumor targets and their corresponding T cell receptors (TCRs) in one or more types of cancer. These tumor targets and TCRs may then be engineered and developed into potent and selective cancer therapies.
Lilly entered a global collaboration and license agreement with Halozyme to develop and commercialize products combining its proprietary compounds with Halozyme’s Enhanze platform to aid in the dispersion and absorption of other injected therapeutic drugs. For Lilly, this technology may allow for more rapid delivery of injectable medications through subcutaneous delivery.
Toward the end of the year, Lilly and Merck extended an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s Alimta (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) in a Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). The expansion of this oncology trial collaboration follows encouraging data from a Phase I study, which evaluated pemetrexed, carboplatin and pembrolizumab in first-line nonsquamous NSCLC.
Lilly and AstraZeneca also extended their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of solid tumors. The companies will now evaluate the safety and efficacy of a range of additional combinations across their portfolios. Lilly will lead the studies and both companies will contribute resources. Earlier in the year, the companies entered a Phase I clinical trial collaboration to evaluate the safety and preliminary efficacy of combining durvalumab and ramucirumab as a treatment for patients with advanced solid tumors.
R&D expansions
In November Lilly unveiled plans to expand its global R&D headquarters in Indianapolis, IN, adding 130,000 square feet to its existing complex. The $70 million investment will feature a multi-disciplinary lab that facilitates collaboration across multiple research functions. The new building is part of Lilly’s continued growth of its Indianapolis footprint, which included a $400 million expansion initiated in 2013 to increase its insulin manufacturing capacity.
When complete in 2017, the new building will enable chemists and engineers to work together a collaboration-centric workspace with modelling, analytical and formulation scientists. The company’s strategy incorporates flexible labs that can adapt as research and technology needs evolve, as well as open, interactive meeting spaces that are meant to promote multi-disciplinary problem-solving.
The lab will focus its efforts on small molecules, which currently comprise about half of Lilly’s investigational drug portfolio.
In May, Lilly unveiled plans to establish a new drug delivery and device innovation center in Cambridge, MA, which was opened by year’s end. The Lilly Cambridge Innovation Center is designed to allow life science organizations to explore how emerging technologies and connectivity can advance drug delivery and device innovation. The center increases the company’s delivery and device R&D space by nearly 50% and increasing staff by 25%.
According to the company, the center will serve as a portal for external partnerships and collaboration activities with the company’s existing research facilities in San Diego, New York City and Indianapolis. During the year Lilly also said it expanded the San Diego biotech center as well as its presence at the Alexandria Center for Life Science in New York, NY.
More than half of the company’s pipeline now comprises biologics that require some type of injection. The company expects its revenues from device-enabled products to double by 2020.
twitter.com/EliLillyCo
www.lilly.com
Headcount: 41,000
Year Established: 1876
Revenues: $19,959 (+2%)
Net Income: $2,408 (+1%)
R&D: $4,796 (+1%)
TOP SELLING DRUGS
Drug | Indication | 2015 Sales | (+/-%) |
Alimta | cancer | $2,493 | -11% |
Humalog | diabetes | $2,842 | 2% |
Cialis | erectile dysfunction | $2,311 | 1% |
Cymbalta | anxiety, depression | $1,028 | -36% |
Humulin | diabetes | $1,307 | -7% |
Forteo | osteoporosis | $1,348 | 2% |
Zyprexa | schizophrenia | $940 | -9% |
Strattera | ADHD | $784 | 6% |
Effient | anticoagulant | $523 | 0% |
Erbitux | head and neck cancer | $485 | 30% |
In 2015 Lilly returned to revenue growth, led by Cyramza and Trulicity following their launches, with significant contributions from its enlarged animal health business, which got a boost after it completed the acquisition of Novartis Animal Health for $5.28 billion at the start of the year under review. Revenue increased 2 percent to $19.96 billion, with six products topping $1 billion in annual sales.
Lilly also reported positive advances in its pipeline of molecules in clinical development. Highlights include: in diabetes, positive cardiovascular outcomes data for Jardiance; in immunology, four positive Phase III studies on baricitinib and strong Phase III data on ixekizumab; and in oncology, Breakthrough Therapy Designation for olaratumab and abemaciclib, several important business development deals in immuno-oncology, and the approval of Portrazza for the treatment of metastatic squamous non-small cell lung cancer late in the year.
The year was active for Lilly on the collaboration front, which saw it expand already existing agreements and form new alliances as well. With Innovent Biologics, Lilly has in place a plan to develop and commercialize a portfolio of cancer treatments. In 2015 the two companies expanded the drug development collaboration, already one of the largest in China between a multi-national and domestic biopharmaceutical company. The companies said they will collaborate to support the development and potential commercialization of up to three anti-PD-1 based bispecific antibodies for cancer treatments over the next decade, both inside and outside of China. Lilly will exercise its rights to develop, manufacture and commercialize these potential cancer treatments outside of China, while Innovent will now have the rights to develop, manufacture and commercialize these potential cancer treatments for China.
Also in China, WuXi PharmaTech (Cayman) and Lilly entered into a strategic collaboration to develop, manufacture and commercialize a novel small molecule. The once-daily oral agent, discovered by Lilly, has the potential to address cardiovascular risk in patients with dyslipidemia. An estimated 276 million patients in China are affected by these conditions. The drug aims to reduce cardiovascular events in patients with elevated LDL cholesterol and triglycerides at high risk of cardiovascular events. WuXi will be responsible for regulatory, development and manufacturing activities in China and Lilly will be responsible for commercial activities. Both companies will invest in this potential new medicine in China. An Investigational New Drug (IND) application will be filed in China by WuXi, and product development and registration will take place within China.
A collaboration agreement was formed with Hanmi to develop and commercialize Hanmi’s compound being investigated for the treatment of autoimmune and other diseases. Lilly received rights to the molecule for all indications on a worldwide basis excluding China, Hong Kong, Taiwan, and Korea, and will be responsible for leading development, regulatory, manufacturing, and commercial efforts in our territories.
Another research collaboration with BioNTech aims to discover novel cancer immunotherapies. The companies will collaborate to identify and validate tumor targets and their corresponding T cell receptors (TCRs) in one or more types of cancer. These tumor targets and TCRs may then be engineered and developed into potent and selective cancer therapies.
Lilly entered a global collaboration and license agreement with Halozyme to develop and commercialize products combining its proprietary compounds with Halozyme’s Enhanze platform to aid in the dispersion and absorption of other injected therapeutic drugs. For Lilly, this technology may allow for more rapid delivery of injectable medications through subcutaneous delivery.
Toward the end of the year, Lilly and Merck extended an existing collaboration to evaluate the safety and efficacy of the combination of Lilly’s Alimta (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) in a Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). The expansion of this oncology trial collaboration follows encouraging data from a Phase I study, which evaluated pemetrexed, carboplatin and pembrolizumab in first-line nonsquamous NSCLC.
Lilly and AstraZeneca also extended their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of solid tumors. The companies will now evaluate the safety and efficacy of a range of additional combinations across their portfolios. Lilly will lead the studies and both companies will contribute resources. Earlier in the year, the companies entered a Phase I clinical trial collaboration to evaluate the safety and preliminary efficacy of combining durvalumab and ramucirumab as a treatment for patients with advanced solid tumors.
R&D expansions
In November Lilly unveiled plans to expand its global R&D headquarters in Indianapolis, IN, adding 130,000 square feet to its existing complex. The $70 million investment will feature a multi-disciplinary lab that facilitates collaboration across multiple research functions. The new building is part of Lilly’s continued growth of its Indianapolis footprint, which included a $400 million expansion initiated in 2013 to increase its insulin manufacturing capacity.
When complete in 2017, the new building will enable chemists and engineers to work together a collaboration-centric workspace with modelling, analytical and formulation scientists. The company’s strategy incorporates flexible labs that can adapt as research and technology needs evolve, as well as open, interactive meeting spaces that are meant to promote multi-disciplinary problem-solving.
The lab will focus its efforts on small molecules, which currently comprise about half of Lilly’s investigational drug portfolio.
In May, Lilly unveiled plans to establish a new drug delivery and device innovation center in Cambridge, MA, which was opened by year’s end. The Lilly Cambridge Innovation Center is designed to allow life science organizations to explore how emerging technologies and connectivity can advance drug delivery and device innovation. The center increases the company’s delivery and device R&D space by nearly 50% and increasing staff by 25%.
According to the company, the center will serve as a portal for external partnerships and collaboration activities with the company’s existing research facilities in San Diego, New York City and Indianapolis. During the year Lilly also said it expanded the San Diego biotech center as well as its presence at the Alexandria Center for Life Science in New York, NY.
More than half of the company’s pipeline now comprises biologics that require some type of injection. The company expects its revenues from device-enabled products to double by 2020.